Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
1,003 ^USD	+0.22%		+2.33%	+14.19%

05/06	Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing	MT
05/06	Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM

Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire

April 17, 2023 at 05:45 pm IST

By Colin Kellaher

Regeneron Pharmaceuticals Inc. on Monday said its longtime chairman, P. Roy Vagelos, plans to retire in June.

The Tarrytown, N.Y., biotechnology company said Mr. Vagelos, who has been chairman since January 1995, will complete his current term but won't stand for re-election at the annual shareholder meeting on June 9.

Regeneron said its founders, Leonard Schleifer and George Yancopoulos, will become co-chairmen in addition to their current posts.

Mr. Schleifer, who is currently chief executive and co-president, served as chairman before Mr. Vagelos joined the company after retiring from drugmaker Merck & Co. Mr. Yancopoulos is currently co-president and chief scientific officer.

Regeneron also said Christine Poon, a board member since 2010, would become lead independent director.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

04-17-23 0814ET

Latest news about Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing	06/06	MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM	05/06
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185	04/06	MT
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier	04/06	MT
FibroGen To Begin Trials on Tumor Treatment After FDA OK	04/06	DJ
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials	04/06	CI
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	31/05	RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee	31/05	MT
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	31/05	MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.	31/05	DJ
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	31/05	CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	31/05	CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing	30/05	MT
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	24/05	MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075	24/05	CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing	23/05	MT
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate	21/05	MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115	21/05	MT
Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine	20/05	CI
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25	20/05	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing	18/05	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing	18/05	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	18/05	MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060	18/05	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing	16/05	MT

Chart Regeneron Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Sector

Biotechnology & Medical Research

Calendar

11/06/2024 - Goldman Sachs Global Healthcare Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,003 USD

Average target price

1,043 USD

Spread / Average Target

+3.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B
INSMED INCORPORATED	+83.45%	9.17B

Bio Therapeutic Drugs